Background: Emotional inhibition has been an enduring concept in the psychosomatic literature explaining the onset and course of medical disorders. Currently the personality style of alexithymia is a focus of this dimension in psychosomatic theory, while actual conscious emotional inhibition, which may overlap with alexithymia, has received less attention. In the early 80s Robert Kellner developed the Emotional Inhibition Scale (EIS), a self-rating scale for emotional inhibition based on clinimetric principles. In this study we explored whether the EIS differentiated a sample of cardiac recipients from normal controls, as well as the associations between the EIS and 2 measures of alexithymia, i.e. the Toronto Alexithymia Scale-20 (TAS-20) and the Diagnostic Criteria for Psychosomatic Research (DCPR). We also examined whether the EIS and the TAS-20 were differently related to depressive symptoms measured by the Symptom Questionnaire (SQ). Methods: Ninety-five heart-transplanted patients and a sample of normal controls, matched for sociodemographic variables, were administered the EIS (total score and 4 subscales concerning ‘verbal inhibition’, ‘timidity’, ‘disguise of feelings’, and ‘self-control’), the TAS-20, the SQ, and the Structured Interview according to the DCPR for alexithymia. Results: Cardiac recipients did not display significant differences compared to normal controls in observer (DCPR) and self-rated (TAS-20) measures of alexithymia. There were, however, significant differences in EIS with regard to ‘disguise of feelings’. In both groups the EIS ‘verbal inhibition’ and ‘timidity’ subscales were positively associated with the TAS-20, while the EIS ‘disguise of feelings’ and ‘self-control’ subscales were independent of alexithymia. Depressive symptoms were more related to TAS-20 than EIS total scores. Conclusions: Our results suggest that emotional inhibition and alexithymia are distinct phenomena even though they may share certain features. The EIS appears to be relatively independent of depressed mood and will be useful in assessing the individual’s conscious management of affect in future psychosomatic research.

Keywords:
Emotional inhibition, Heart transplantation, Affect, Alexithymia, Clinimetrics, Depression, Diagnostic Criteria for Psychosomatic Research
1.
Sifneos PE: The prevalence of ‘alexithymic’ characteristics in psychosomatic patients. Psychother Psychosom 1973;22:255–262.
2.
Sifneos PE: Alexithymia, clinical issues, politics and crime. Psychother Psychosom 2000;69:113–116.
3.
Taylor GJ, Bagby RM, Parker JD: The alexithymia construct: a potential paradigm for psychosomatic medicine. Psychosomatics 1991;32:153–164.
4.
Taylor GJ: Affects, trauma, and mechanisms of symptom formation: a tribute to John C. Nemiah, MD (1918–2009). Psychother Psychosom 2010;79:339–349.
5.
Taylor GJ, Bagby RM: New trends in alexithymia research. Psychother Psychosom 2004;73:68–77.
6.
Taylor GJ, Ryan D, Bagby RM: Toward the development of a new self-report alexithymia scale. Psychother Psychosom 1985;44:191–199.
7.
Bagby RM, Parker JD, Taylor GJ: The twenty-item Toronto Alexithymia Scale-I: item selection and cross-validation of the factor structure. J Psychosom Res 1994;38:23–32.
8.
Bagby RM, Taylor GJ, Parker JD: The twenty-item Toronto Alexithymia Scale-II: convergent, discriminant, and concurrent validity. J Psychosom Res 1994;38:33–40.
9.
Bermond B, Vorst HC, Vingerhoets AJ, Gerritsen W: The Amsterdam Alexithymia Scale: its psychometric values and correlations with other personality traits. Psychother Psychosom 1999;68:241–251.
10.
Vorst HC, Bermond B: Validity and reliability of the Bermond-Vorst Alexithymia Questionnaire. Pers Indiv Dif 2001;30:413–434.
11.
Kleiger JH, Kinsman RA: The development of an MMPI alexithymia scale. Psychother Psychosom 1980;34:17–24.
12.
Apfel RJ, Sifneos PE: Alexithymia: concept and measurement. Psychother Psychosom 1979;32:180–190.
13.
Martin JB, Pihl RO, Dobkin P: Schalling-Sifneos personality scale: findings and recommendations. Psychother Psychosom 1984;41:145–152.
14.
Bagby RM, Taylor GJ, Parker JD, Dickens SE: The development of the Toronto Structured Interview for Alexithymia: item selection, factor structure, reliability and concurrent validity. Psychother Psychosom 2006;75:25–39.
15.
Haviland MG, Warren WL, Riggs ML: An observer scale to measure alexithymia. Psychosomatics 2000;41:385–392.
16.
Cohen K, Auld F, Demers L, Catchlove R: Alexithymia: the development of a valid and reliable projective measure (the objectively scored Archetypal9 Test). J Nerv Ment Dis 1985;173:621–627.
17.
Porcelli P, Meyer GJ: Construct validity of Rorschach variables for alexithymia. Psychosomatics 2002;43:360–369.
18.
Porcelli P, Mihura JL: Assessment of alexithymia with the Rorschach Comprehensive System: the Rorschach Alexithymia Scale (RAS). J Pers Assess 2010;92:128–136.
19.
Taylor GJ, Bagby RM: Measurement of alexithymia: recommendations for clinical practice and future research. Psychiatr Clin North Am 1988;11:351–366.
20.
Kooiman CG, Spinhoven P, Trijsburg RW: The assessment of alexithymia: a critical review of the literature and a psychometric study of the Toronto Alexithymia Scale-20. J Psychosom Res 2002;53:1083–1090.
21.
Müller J, Bühner M, Ellgring H: Is there a reliable factorial structure in the 20-item Toronto Alexithymia Scale? A comparison of factor models in clinical and normal adult samples. J Psychosom Res 2003;55:561–568.
22.
Haviland MG, Reise SP: Structure of the twenty-item Toronto Alexithymia Scale. J Pers Assess 1996;66:116–125.
23.
Loas G, Otmani O, Verrier A, Fremaux D, Marchand MP: Factor analysis of the French version of the 20-Item Toronto Alexithymia Scale (TAS-20). Psychopathology 1996;29:139–144.
24.
Erni T, Lötscher K, Modestin J: Two-factor solution of the 20-item Toronto Alexithymia Scale confirmed. Psychopathology 1997;30:335–340.
25.
Hintikka J, Honkalampi K, Lehtonen J, Viinamäki H: Are alexithymia and depression distinct or overlapping constructs? A study in a general population. Compr Psychiatry 2001;42:234–239.
26.
Joukamaa M, Miettunen J, Kokkonen P, Koskinen M, Julkunen J, Kauhanen J, Jokelainen J, Veijola J, Läksy K, Järvelin MR: Psychometric properties of the Finnish 20-item Toronto Alexithymia Scale. Nord J Psychiatry 2001;55:123–127.
27.
Wise TN, Jani NN, Kass E, Sonnenschein K, Mann LS: Alexithymia: relationship to severity of medical illness and depression. Psychother Psychosom 1988;50:68–71.
28.
Honkalampi K, Hintikka J, Saarinen P, Lehtonen J, Viinamäki H: Is alexithymia a permanent feature in depressed patients? Psychother Psychosom 2000;69:303–308.
29.
Honkalampi K, Koivumaa-Honkanen H, Tanskanen A, Hintikka J, Lehtonen J, Viinamäki H: Why do alexithymic features appear to be stable? A 12-month follow-up study of a general population. Psychother Psychosom 2001;70:247–253.
30.
Honkalampi K, Lehto SM, Hintikka J, Koivumaa-Honkanen H, Niskanen L, Viinamäki H: Symptoms of depression and alexithymic burden in middle-aged men. Psychother Psychosom 2010;79:259–261.
31.
Wise TN, Mann LS, Mitchell JD, Hryvniak M, Hill B: Secondary alexithymia: an empirical validation. Compr Psychiatry 1990;31:284–288.
32.
Freyberger H: Supportive psychotherapeutic techniques in primary and secondary alexithymia. Psychother Psychosom 1977;28:337–342.
33.
Engel GL, Schmale AH: Conservation-withdrawal: a primary regulatory process for organismic homeostasis. Ciba Found Symp 1972;8:57–75.
34.
Sirri L, Grandi S, Fava GA: The Illness Attitude Scales: a clinimetric index for assessing hypochondriacal fears and beliefs. Psychother Psychosom 2008;77:337–350.
35.
Fava GA, Ruini C, Rafanelli C: Psychometric theory is an obstacle to the progress of clinical research. Psychother Psychosom 2004;73:145–148.
36.
Bech P: Fifty years with the Hamilton scales for anxiety and depression: a tribute to Max Hamilton. Psychother Psychosom 2009;78:202–211.
37.
Fava GA, Sonino N: Psychosomatic assessment. Psychother Psychosom 2009;78:333–341.
38.
Fava GA, Guidi J, Semprini F, Tomba E, Sonino N: Clinical assessment of allostatic load and clinimetric criteria. Psychother Psychosom 2010;79:280–284.
39.
Fava GA, Rafanelli C, Tomba E: The clinical process in psychiatry: a clinimetric approach. J Clin Psychiatry, in press.
40.
Pennebaker JW, Hughes CF, O’Heeron RC: The psychophysiology of confession: linking inhibitory and psychosomatic processes. J Pers Soc Psychol 1987;52:781–793.
41.
Pennebaker JW, Kiecolt-Glaser JK, Glaser R: Disclosure of traumas and immune function: health implications for psychotherapy. J Consult Clin Psychol 1988;56:239–245.
42.
Fava GA, Grandi S, Savron G, Bartolucci G, Santarsiero G, Trombini G, Orlandi C: Psychosomatic assessment of hirsute women. Psychother Psychosom 1989;51:96–100.
43.
Saviotti FM, Grandi S, Savron G, Ermentini R, Bartolucci G, Conti S, Fava GA: Characterological traits of recovered patients with panic disorder and agoraphobia. J Affect Disord 1991;23:113–117.
44.
Hollifield M, Tuttle L, Paine S, Kellner R: Hypochondriasis and somatization related to personality and attitudes toward self. Psychosomatics 1999;40:387–395.
45.
Fava GA, Freyberger HJ, Bech P, Christodoulou G, Sensky T, Theorell T, Wise TN: Diagnostic criteria for use in psychosomatic research. Psychother Psychosom 1995;63:1–8.
46.
Porcelli P, Rafanelli C: Criteria for psychosomatic research (DCPR) in the medical setting. Curr Psychiatry Rep 2010;12:246–254.
47.
Wise TN: Diagnostic criteria for psychosomatic research are necessary for DSM V. Psychother Psychosom 2009;78:330–332.
48.
Porcelli P, Sonino N (eds): Psychological Factors Affecting Medical Conditions: A New Classification for DSM-V. Adv Psychosom Med. Basel, Karger, 2007, vol 28, pp I–X.
49.
Porcelli P, De Carne M, Fava GA: Assessing somatization in functional gastrointestinal disorders: integration of different criteria. Psychother Psychosom 2000;69:198–204.
50.
Grandi S, Fabbri S, Tossani E, Mangelli L, Branzi A, Magelli C: Psychological evaluation after cardiac transplantation: the integration of different criteria. Psychother Psychosom 2001;70:176–183.
51.
Grassi L, Sabato S, Rossi E, Biancosino B, Marmai L: Use of the diagnostic criteria for psychosomatic research in oncology. Psychother Psychosom 2005;74:100–107.
52.
Grassi L, Mangelli L, Fava GA, Grandi S, Ottolini F, Porcelli P, Rafanelli C, Rigatelli M, Sonino N: Psychosomatic characterization of adjustment disorders in the medical setting: some suggestions for DSM-V. J Affect Disord 2007;101:251–254.
53.
Galeazzi GM, Ferrari S, Mackinnon A, Rigatelli M: Interrater reliability, prevalence, and relation to ICD-10 diagnoses of the diagnostic criteria for psychosomatic research in consultation-liaison psychiatry patients. Psychosomatics 2004;45:386–393.
54.
Porcelli P, Bellomo A, Quartesan R, Altamura M, Iuso S, Ciannameo I, Piselli M, Elisei S: Psychosocial functioning in consultation-liaison psychiatry patients: influence of psychosomatic syndromes, psychopathology and somatization. Psychother Psychosom 2009;78:352–358.
55.
Mangelli L, Semprini F, Sirri L, Fava GA, Sonino N: Use of the diagnostic criteria for psychosomatic research (DCPR) in a community sample. Psychosomatics 2006;47:143–146.
56.
Fukunishi I, Hosaka T, Aoki T, Azekawa T, Ota A, Miyaoka H: Criterion-related validity of diagnostic criteria for alexithymia in a general hospital psychiatric setting. Psychother Psychosom 1996;65:82–85.
57.
Porcelli P, De Carne M: Criterion-related validity of the diagnostic criteria for psychosomatic research for alexithymia in patients with functional gastrointestinal disorders. Psychother Psychosom 2001;70:184–188.
58.
Beresnevaité M, Taylor GJ, Bagby RM: Assessing alexithymia and type A behavior in coronary heart disease patients: a multimethod approach. Psychother Psychosom 2007;76:186–192.
59.
Bressi C, Taylor G, Parker J, Bressi S, Brambilla V, Aguglia E, Allegranti I, Bongiorno A, Giberti F, Bucca M, Todarello O, Callegari C, Vender S, Gala C, Invernizzi G: Cross validation of the factor structure of the 20-item Toronto Alexithymia Scale: an Italian multicenter study. J Psychosom Res 1996;41:551–559.
60.
Kellner R: A symptom questionnaire. J Clin Psychiatry 1987;48:268–273.
61.
Fava GA, Kellner R, Perini GI, Fava M, Michelacci L, Munari F, Evangelisti LP, Grandi S, Bernardi M, Mastrogiacomo I: Italian validation of the Symptom Rating Test (SRT) and Symptom Questionnaire (SQ). Can J Psychiatry 1983;28:117–123.
62.
Fava GA, Kellner R, Lisansky J, Park S, Perini GI, Zielezny M: Rating depression in normals and depressives: observer versus self-rating scales. J Affect Disord 1986;11:29–33.
63.
Pennebaker JW, Beall SK: Confronting a traumatic event: toward an understanding of inhibition and disease. J Abnorm Psychol 1986;95:274–281.
64.
King LA, Emmons RA, Woodley S: The structure of inhibition. J Res Pers 1992;26:85–102.
65.
Davies M, Stankov L, Roberts RD: Emotional intelligence: in search of an elusive construct. J Pers Soc Psychol 1998;75:989–1015.
66.
Helmes E, McNeill PD, Holden RR, Jackson C: The construct of alexithymia: associations with defense mechanisms. J Clin Psychol 2008;64:318–331.
67.
Verissimo R, Mota-Cardoso R, Taylor G: Relationships between alexithymia, emotional control, and quality of life in patients with inflammatory bowel disease. Psychother Psychosom 1998;67:75–80.
68.
Myers LB: Alexithymia and repression: the role of defensiveness and trait anxiety. Pers Individ Dif 1995;19:489–492.
69.
Martin JB, Pihl RO: Influence of alexithymic characteristics on physiological and subjective stress responses in normal individuals. Psychother Psychosom 1986;45:66–77.
70.
Papciak AS, Feuerstein M, Spiegel JA: Stress reactivity in alexithymia: decoupling of physiological and cognitive responses. J Human Stress 1985;11:135–142.
71.
Newton TL, Contrada RJ: Alexithymia and repression: contrasting emotion-focused coping styles. Psychosom Med 1994;56:457–462.
72.
Dew MA: Quality-of-life studies: organ transplantation research as an exemplar of past progress and future directions. J Psychosom Res 1998;44:189–195.
73.
Weisman AD, Hackett TP: Denial as a social act; in Levin S, Kahana R (eds): Psychodynamic Studies on Aging: Creativity, Reminiscing and Dying. New York, IUP, 1967, pp 79–110.
74.
Michael YL, Wisdom JP, Perrin N, Bowen D, Cochrane BB, Brzyski R, Ritenbaugh C: Expression and ambivalence over expression of negative emotion: cross-sectional associations with psychosocial factors and health-related quality of life in postmenopausal women. J Women Aging 2006;18:25–40.
75.
Iwamitsu Y, Shimoda K, Abe H, Tani T, Kodama M, Okawa M: Differences in emotional distress between breast tumor patients with emotional inhibition and those with emotional expression. Psychiatry Clin Neurosci 2003;57:289–294.
76.
Iwamitsu Y, Shimoda K, Abe H, Tani T, Okawa M, Buck R: The relation between negative emotional suppression and emotional distress in breast cancer diagnosis and treatment. Health Commun 2005;18:201–215.
77.
Jensen MR: Psychobiological factors predicting the course of breast cancer. J Pers 1987;55:317–342.
78.
Giese-Davis J, DiMiceli S, Sephton S, Spiegel D: Emotional expression and diurnal cortisol slope in women with metastatic breast cancer in supportive-expressive group therapy: a preliminary study. Biol Psychol 2006;73:190–198.
79.
Shaw RE, Cohen F, Doyle B, Palesky J: The impact of denial and repressive style on information gain and rehabilitation outcomes in myocardial infarction patients. Psychosom Med 1985;47:262–273.
80.
Esterling BA, Antoni MH, Kumar M, Schneiderman N: Emotional repression, stress disclosure responses, and Epstein-Barr viral capsid antigen titers. Psychosom Med 1990;52:397–410.
81.
King AC, Taylor CB, Albright CA, Haskell WL: The relationship between repressive and defensive coping styles and blood pressure responses in healthy, middle-aged men and women. J Psychosom Res 1990;34:461–471.
82.
Niaura R, Herbert PN, McMahon N, Sommerville L: Repressive coping and blood lipids in men and women. Psychosom Med 1992;54:698–706.
83.
Berry DS, Pennebaker JW: Nonverbal and verbal emotional expression and health. Psychother Psychosom 1993;59:11–19.
84.
Gross JJ, Levenson RW: Hiding feelings: the acute effects of inhibiting negative and positive emotion. J Abnorm Psychol 1997;106:95–103.
85.
Myers LB: The importance of the repressive coping style: findings from 30 years of research. Anxiety Stress Coping 2010;23:3–17.
86.
Denollet J: Personality and risk of cancer in men with coronary heart disease. Psychol Med 1998;28:991–995.
87.
Kupper N, Denollet J: Type D personality as a prognostic factor in heart disease: assessment and mediating mechanisms. J Pers Assess 2007;89:265–276.
88.
Lumley MA, Stettner L, Wehmer F: How are alexithymia and physical illness linked? A review and critique of pathways. J Psychosom Res 1996;41:505–518.
89.
Sifneos PE: Problems of psychotherapy of patients with alexithymic characteristics and physical disease. Psychother Psychosom 1975;26:65–70.
90.
Beresnevaité M: Exploring the benefits of group psychotherapy in reducing alexithymia in coronary heart disease patients: a preliminary study. Psychother Psychosom 2000;69:117–122.
91.
Stingl M, Bausch S, Walter B, Kagerer S, Leichsenring F, Leweke F: Effects of inpatient psychotherapy on the stability of alexithymia characteristics. J Psychosom Res 2008;65:173–180.
92.
Grabe HJ, Frommer J, Ankerhold A, Ulrich C, Groger R, Franke GH, Barnow S, Freyberger HJ, Spitzer C: Alexithymia and outcome in psychotherapy. Psychother Psychosom 2008;77:189–194.
93.
Tulipani C, Morelli F, Spedicato MR, Maiello E, Todarello O, Porcelli P: Alexithymia and cancer pain: the effect of psychological intervention. Psychother Psychosom 2010;79:156–163.
94.
Ogrodniczuk JS, Piper WE, Joyce AS, Abbass AA: Alexithymia and treatment preferences among psychiatric outpatients. Psychother Psychosom 2009;78:383–384.
95.
Smyth JM: Written emotional expression: effect sizes, outcome types, and moderating variables. J Consult Clin Psychol 1998;66:174–184.
96.
Frisina PG, Borod JC, Lepore SJ: A meta-analysis of the effects of written emotional disclosure on the health outcomes of clinical populations. J Nerv Ment Dis 2004;192:629–634.
97.
Frattaroli J: Experimental disclosure and its moderators: a meta-analysis. Psychol Bull 2006;132:823–865.
98.
van Middendorp H, Geenen R, Sorbi MJ, van Doornen LJ, Bijlsma JW: Health and physiological effects of an emotional disclosure intervention adapted for application at home: a randomized clinical trial in rheumatoid arthritis. Psychother Psychosom 2009;78:145–151.
99.
Wise TN, Mann LS, Hill B: Alexithymia and depressed mood in the psychiatric patient. Psychother Psychosom 1990;54:26–31.
100.
Parker JD, Bagby RM, Taylor GJ: Alexithymia and depression: distinct or overlapping constructs? Compr Psychiatry 1991;32:387–394.
101.
Wise TN, Mann LS, Randell P: The stability of alexithymia in depressed patients. Psychopathology 1995;28:173–176.
102.
Luminet O, Bagby RM, Taylor GJ: An evaluation of the absolute and relative stability of alexithymia in patients with major depression. Psychother Psychosom 2001;70:254–260.
103.
Lynch TR, Robins CJ, Morse JQ, Krause ED: A mediational model relating affect intensity, emotional inhibition, and psychological distress. Behav Ther 2001;32:519–536.
104.
Krause ED, Mendelson T, Lynch TR: Childhood emotional invalidation and adult psychological distress: the mediating role of emotional inhibition. Child Abuse Negl 2003;27:199–213.
105.
Van Emmerik AA, Kamphuis JH, Emmelkamp PM: Treating acute stress disorder and posttraumatic stress disorder with cognitive behavioral therapy or structured writing therapy: a randomized controlled trial. Psychother Psychosom 2008;77:93–100.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.